Multimer Reagent for Specific CAR-T Cell Detection and Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapy faces challenges such as non-specific binding of existing CAR-staining reagents, protein instability, high developmental costs, and low yield due to incomplete CAR transfection and toxicity from magnetic beads, leading to compromised purity and function of CAR-T cells.
Innovation Solution
A multimer-based reagent system comprising a scaffold protein with streptavidin binding capabilities, specifically designed for high-affinity detection and expansion of CAR-expressing cells, including CAR-T cells, using biotin-tagged antigens and various forms of multimers like tetramers and dodecamers to enhance specificity, sensitivity, and precision.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If generic CAR-staining reagents (polyclonal anti-IgG antibodies and Protein L) are used, then broad compatibility is achieved, but non-specific binding and multi-step staining procedures occur
Solution Approach 1:
The patent introduces an intermediary molecule (Fc region of antibody) that mediates between the staining reagent and CAR. The Fc-specific binding reagent binds to the Fc region of the antibody component of CAR, providing specific detection without direct interaction with the antigen-binding region, thereby eliminating non-specific binding while maintaining compatibility
Solution Approach 2:
The patent creates a simplified copy of the CAR structure by targeting only the Fc region of the antibody component, rather than requiring the entire CAR structure or antigen interaction. This copying approach allows specific detection through a standardized, easily accessible epitope that mimics the structural features of CAR without requiring complex multi-step procedures
2Reliability
If specific CAR-staining reagents (target antigen and anti-idiotype antibodies) are used, then high specificity is achieved, but protein instability and high developmental cost occur
Solution Approach 1:
The patent employs a standardized Fc-specific binding reagent that can be used repeatedly and is stable under various conditions. Unlike expensive and unstable anti-idiotype antibodies, the Fc-binding reagent targets a conserved region that is easily accessible and stable, reducing developmental costs and improving protein stability while maintaining high specificity
Solution Approach 2:
The patent changes the binding parameter from targeting variable regions (anti-idiotype) or native antigens to targeting the constant Fc region. This parameter change transforms the staining approach from one requiring highly specific, unstable proteins to one using stable, standardized reagents that bind to invariant structural features of the antibody component
3Productivity
If magnetic bead-conjugated anti-CD3/CD28 antibodies are used for T cell stimulation, then T cell activation is achieved, but toxicity and non-specific expansion occur
Solution Approach 1:
The patent extracts the essential function of T cell stimulation (CD3 and CD28 co-stimulation) from the problematic magnetic bead system. By using soluble multimeric complexes of CD3 and CD28 ligands, the patent removes the toxic magnetic bead component while retaining the cell activation function, thereby eliminating toxicity while maintaining productivity
Solution Approach 2:
The patent introduces multimeric CD3/CD28 ligand complexes as intermediaries that mediate T cell activation without requiring magnetic beads. These soluble multimers serve as intermediaries that transfer the activation signal from the ligands to the T cell receptors, achieving cell expansion without the harmful effects of magnetic bead retention
4Quantity of substance
If lentivirus transduction is used for CAR delivery, then CAR expression is achieved, but incomplete transfection and low yield occur
Solution Approach 1:
The patent uses multimeric CD3/CD28 ligand complexes as intermediaries to enhance CAR expression after transduction. These multimers provide sustained co-stimulation that improves transfection efficiency and CAR expression levels, addressing the incomplete transfection problem without changing the delivery method itself
Solution Approach 2:
The patent employs composite multimeric structures combining CD3 and CD28 ligands in specific ratios and configurations. This composite approach creates a synergistic effect where the combination of multiple signaling components enhances transfection efficiency and CAR expression beyond what single ligands can achieve
5Reliability
If anti-CD19 CAR is used for target recognition, then cancer cell specificity is achieved, but binding affinity is limited by ≤2-valency
Solution Approach 1:
The patent merges multiple antigen-binding sites into a single multimeric complex, combining CD3 and CD28 ligands with multiple antigen-binding units. This merging increases the valency from ≤2 to higher orders, thereby strengthening binding affinity while maintaining the specificity of anti-CD19 CAR through the preserved antigen-recognition domains
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multimer system enables highly specific, sensitive, and precise detection and expansion of CAR-expressing cells, reducing non-specific binding and toxicity, and improving the purity and function of CAR-T cells, facilitating their clinical application.
Implementation Method 1
A multimer-based reagent system comprising a scaffold protein with streptavidin binding capabilities, specifically designed for high-affinity detection and expansion of CAR-expressing cells, including CAR-T cells, using biotin-tagged antigens
Data Source
AI summary
The present invention discloses a versatile application of a multimer technology for detecting, manufacturing, and profiling chimeric antigen receptor (CAR)-expressing cells. These antigen-multimers exhibit remarkable specificity, sensitivity, and precision in identifying CAR cells. Moreover, they facilitate over 100-fold magnetic enrichment of rare CAR-T cells, enhancing their detectability. Beyond CAR detection, the multimer technology selectively stimulates CAR-expressing cells, both in soluble and surface-bound formats, during CAR-T cell manufacturing. Unlike existing technologies (such as anti-CD28/CD3 magnetic beads) that non-specifically stimulate and expand all T cells, the multimer approach ensures that only CAR-expressing cells are targeted. Consequently, this yields a CAR-T cell product with significantly higher purity, enhancing treatment efficacy. Furthermore, the multimer technology offers flexibility in CAR detection through nucleotide labeling. This enables high-dimensional CAR-T cell profiling via single-cell multi-omics analyses. Antigen multimers can be seamlessly adapted to other CAR systems by switching the antigen ligand.